Secukinumab

Red

Brand Name(s):Cosentyx

Indication:Psoriasis (moderate to severe plaque psoriasis)
Psoriatic arthritis Ankylosing spondylitis

Rationale:1,2

Considered:Feb-15

Review Date:Oct-21

Comments:
NICE TA407
For treating active ankylosing spondylitis that has not responded well enough to conventional therapy
Sept 2016
…………………………
NICE technology appraisal guidance [TA350]

Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab (Cosentyx) is recommended as a possible treatment for people with plaque psoriasis if:
*standard assessments show that their psoriasis is severe and is affecting their quality of life, and
*their psoriasis has not improved with other treatments including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these treatments in the past or there is a reason why they cannot have them.

Treatment with secukinumab should be stopped after 12 weeks if the psoriasis does not improve enough according to standard measures.

July 2015